NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblastic leukemia and otherwise had very short life expectancies. Stephan A Grupp, …
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin
In this edition Peter Goodwin and Sara Freeman report from:
European Breast Cancer Conference, Berlin, April 15-19, 2008;
Chemotherapy …
 Francis Giles |  Ken Kaushansky |  Heather Leitch |  Nancy Berliner |
 Corrado Tarella |  Vincent Rajkumar |  Robert Kyle |
REFERENCE: Abstract: 163
FRANCIS GILES, M D Anderson Cancer Center, Houston
COMMENT: KEN
 Martin Müller |  Charles Linker |  Andreas Hochhaus |  Christian Buske |  Katarina Le Blanc |
 Stephen Emerson |  Alessandro Vannucchi |  Kanti Rai |  Richard Schlenk |
REFERENCE: American Society of Hematology 2006 Orlando: Abstract: 748
MARTIN MÜLLER,
 George Canellos |  Sandra Strauss |  Nancy Baxter |
REFERENCES: J Clin Oncol 34:3904, 3927,
Abstract 349
Sandra Horning, Stanford University Medical Center
It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therapy in patients with advanced follicular lymphoma. However, the use of rituximab maintenance, after induction …
Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York
Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAHA which targets BCL-6 in the tumor preventing it’s anti-apoptotic influence; the other …
